Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omacetaxine mepesuccinate in CML patients who failed 2+ TKIs
NCT02078960Phase 2Terminated
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Oct 2014
- Primary completion
- Jul 2017
- Modality
- Nucleic Acid-Directed Small Molecules, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of homoharringtonine in chronic myeloid leukemia (CML), sponsored by Teva Pharmaceutical Industries Ltd.. Started Oct 2014; status: terminated.
02
Drugs
homoharringtonine
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT02078960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02078960.